Literature DB >> 31041885

Comparison of ultra-low dose chest CT scanning protocols for the detection of pulmonary nodules: a phantom study.

Gianluca Milanese1,2, Mario Silva1,2, Thomas Frauenfelder3, Matthias Eberhard3, Federica Sabia2, Chiara Martini4, Alfonso Marchianò5, Mathias Prokop6, Nicola Sverzellati1, Ugo Pastorino2.   

Abstract

PURPOSE: To test ultra-low-dose computed tomography (ULDCT) scanning protocols for the detection of pulmonary nodules (PN).
METHODS: A chest phantom containing 19 solid and 11 subsolid PNs was scanned on a third-generation dual-source computed tomography (CT) scanner. Five ULDCT scans (Sn100kVp and 120, 70, 50, 30, and 20 reference mAs, using tube current modulation), reconstructed with iterative reconstruction (IR) algorithm at strength levels 2, 3, 4, and 5, were compared with standard CT (120kVp, 150 reference mAs, using tube current modulation). PNs were subjectively assessed according to a 4-point scale: 0, nondetectable nodule; 1, detectable nodule, very unlikely to be correctly measured; 2, detectable nodule, likely to be correctly measured; 3, PN quality equal to standard of reference. PN scores were analysed according to the Lung Imaging Reporting and Data System (Lung-RADS), simulating detection of nodules at baseline and incidence screening round.
RESULTS: For the baseline round, there were 17 Lung-RADS 2, 4 Lung-RADS 3, 8 Lung-RADS 4A, and 1 Lung-RADS 4B PNs. They were detectable in any ULDCT protocol, with the exception of 1 nondetectable part-solid nodule in 1 scanning protocol (120 reference mAs; IR strength: 3). For the incidence round, there were 4 Lung-RADS 2, 14 Lung-RADS 3, 2 Lung-RADS 4A, and 10 Lung-RADS 4B PNs. Ten were nondetectable in at least one ULDCT dataset; however, they were at least detectable in ULDCT with 70 reference mAs (IR strength: 4 and 5).
CONCLUSIONS: ULDCT scanning protocols allowing the detection of PNs can be proposed for the purpose of lung cancer screening.

Entities:  

Keywords:  Pulmonary nodules; image reconstruction; radiation dosage; ultra-low-dose computed tomography

Mesh:

Year:  2019        PMID: 31041885     DOI: 10.1177/0300891619847271

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916            Impact factor:   2.098


  5 in total

1.  Longitudinal change during follow-up of systemic sclerosis: correlation between high-resolution computed tomography and pulmonary function tests.

Authors:  Aldo Carnevale; Mario Silva; Elisa Maietti; Gianluca Milanese; Marta Saracco; Simone Parisi; Elena Bravi; Fabio De Gennaro; Eugenio Arrigoni; Flavio Cesare Bodini; Enrico Fusaro; Carlo Alberto Scirè; Nicola Sverzellati; Alarico Ariani
Journal:  Clin Rheumatol       Date:  2020-09-03       Impact factor: 2.980

2.  Lung cancer screening: tell me more about post-test risk.

Authors:  Mario Silva; Gianluca Milanese; Ugo Pastorino; Nicola Sverzellati
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

3.  Differential Diagnosis of Preinvasive Lesions in Small Pulmonary Nodules by Dual Source Computed Tomography Imaging.

Authors:  Hongjun Yan; Ye Hua; Tingcui Zhang; Wen Liu
Journal:  Comput Math Methods Med       Date:  2022-07-04       Impact factor: 2.809

4.  CT angiography for pulmonary embolism in the emergency department: investigation of a protocol by 20 ml of high-concentration contrast medium.

Authors:  Mario Silva; Gianluca Milanese; Rocco Cobelli; Carmelinda Manna; Edoardo Rasciti; Sara Poggesi; Nicola Sverzellati
Journal:  Radiol Med       Date:  2019-10-28       Impact factor: 3.469

5.  Low-dose CT for lung cancer screening: position paper from the Italian college of thoracic radiology.

Authors:  Mario Silva; Giulia Picozzi; Nicola Sverzellati; Sandra Anglesio; Maurizio Bartolucci; Edoardo Cavigli; Annalisa Deliperi; Massimo Falchini; Fabio Falaschi; Domenico Ghio; Paola Gollini; Anna Rita Larici; Alfonso V Marchianò; Stefano Palmucci; Lorenzo Preda; Chiara Romei; Carlo Tessa; Cristiano Rampinelli; Mario Mascalchi
Journal:  Radiol Med       Date:  2022-03-20       Impact factor: 6.313

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.